Clinical implications of p53 mutations

被引:181
作者
Wallace-Brodeur, RR [1 ]
Lowe, SW [1 ]
机构
[1] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
关键词
apoptosis; chemotherapy; prognosis; tumor suppressor; cancer genetics; clinical outcome;
D O I
10.1007/s000180050270
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ultimate goal of basic cancer research is to provide a theoretical foundation for rational approaches to improve cancer therapy. Our extensive insight into the biology of the p53 tumour suppressor and the clinical behaviour of tumours harbouring p53 mutations indicates that information concerning p53 will be useful in diagnosis and prognosis, and may ultimately produce new therapeutic strategies. At the same time, efforts to understand the clinical implications of p53 mutations have revealed conceptual and technical limitations in translating basic biology to the clinic. The lessons learned from p53 may lay the groundwork for future efforts to synthesize cancer gene function, cancer genetics and cancer therapy.
引用
收藏
页码:64 / 75
页数:12
相关论文
共 148 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   PROGNOSTIC-SIGNIFICANCE OF TP53 ALTERATIONS IN BREAST-CARCINOMA [J].
ANDERSEN, TI ;
HOLM, R ;
NESLAND, JM ;
HEIMDAL, KR ;
OTTESTAD, L ;
BORRESEN, AL .
BRITISH JOURNAL OF CANCER, 1993, 68 (03) :540-548
[3]   PREVALENCE OF SERUM ANTIBODIES AGAINST THE P53 TUMOR-SUPPRESSOR GENE PROTEIN IN VARIOUS CANCERS [J].
ANGELOPOULOU, K ;
DIAMANDIS, EP ;
SUTHERLAND, DJA ;
KELLEN, JA ;
BUNTING, PS .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (04) :480-487
[4]   p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein [J].
Backe, J ;
Gassel, AM ;
Hauber, K ;
Krebs, S ;
Bartek, J ;
Caffier, H ;
Kreipe, HH ;
Muller-Hermelink, HK ;
Dietl, J .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1997, 16 (04) :361-368
[5]  
BAIN J, 1997, P NATL ACAD SCI USA, V94, P14753
[6]   EXPRESSION OF MDM-2 AND P53 PROTEIN IN TRANSITIONAL-CELL CARCINOMA [J].
BARBARESCHI, M ;
GIRLANDO, S ;
FELLIN, G ;
GRAFFER, U ;
LUCIANI, L ;
DALLAPALMA, P .
UROLOGICAL RESEARCH, 1995, 22 (06) :349-352
[7]  
BARDEESY N, 1995, CANCER RES, V55, P215
[8]   ANAPLASTIC WILMS-TUMOR, A SUBTYPE DISPLAYING POOR-PROGNOSIS, HARBORS P53 GENE-MUTATIONS [J].
BARDEESY, N ;
FALKOFF, D ;
PETRUZZI, MJ ;
NOWAK, N ;
ZABEL, B ;
ADAM, M ;
AGUIAR, MC ;
GRUNDY, P ;
SHOWS, T ;
PELLETIER, J .
NATURE GENETICS, 1994, 7 (01) :91-97
[9]   EXPRESSION OF THE BCL-2 GENE FAMILY IN NORMAL AND MALIGNANT BREAST-TISSUE - LOW BAX-ALPHA EXPRESSION IN TUMOR-CELLS CORRELATES WITH RESISTANCE TOWARDS APOPTOSIS [J].
BARGOU, RC ;
DANIEL, PT ;
MAPARA, MY ;
BOMMERT, K ;
WAGENER, C ;
KALLINICH, B ;
ROYER, HD ;
DORKEN, B .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (06) :854-859
[10]   ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT [J].
BARNES, DM ;
HANBY, AM ;
GILLETT, CE ;
MOHAMMED, S ;
HODGSON, S ;
BOBROW, LG ;
LEIGH, IM ;
PURKIS, T ;
MACGEOCH, C ;
SPURR, NK ;
BARTEK, J ;
VOJTESEK, B ;
PICKSLEY, SM ;
LANE, DP .
LANCET, 1992, 340 (8814) :259-263